Moneycontrol
    Moneycontrol PRO
    LAMF
    LAMF

    Syngene: How should one position for it after a disappointing quarter?

    The company’s investment in biologics and new modalities is promising. While some of these facilities should start contributing to the bottom line in the near term, the balance sheet remains strong with net cash of about Rs 900 crore

    Anubhav Sahu
    February 16, 2026 / 11:11 IST
    Drag from Zoetis larger than expected
    • PRO Panorama

      Moneycontrol Pro Panorama | War wounds cut deeper

      Mar 30, 2026 / 03:09 PM IST

      In this edition of Moneycontrol Pro Panorama: Fed futures price prolonged Iran conflict risks; RBI move curbs forex arbitrage, rai...

      Read Now
    Unlock This Article

    Are you a PRO subscriber? Sign In

    What Do You Get

    • Ad free Experience

      Seamless navigation, faster responses.

    • Expert Perspective

      Explore 230+ exclusive editorials every month

    • +

      Uncover Insights from World-Renowned Experts and Journalists

    • Actionable Insights

      40+ weekly investment ideas + 3 to 4 daily technical calls

    • Virtual Events

      Exclusive Live Webinars for Expert Trading & Investment Strategies!

    • Newsletters

      Stay ahead with daily and weekly insights

    View Offers

    Unlock exclusive discounts

    Disclosure & Disclaimer

    This Research Report / Research Recommendation has been published by Moneycontrol Dot Com India Limited (hereinafter referred to as “MCD”) which is a registered Investment Advisor under the Securities and Exchange Board of India (Investment Advisers) ...Read More